Literature DB >> 22727601

Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies.

Stephanie Du Four1, Sofie Wilgenhof, Johnny Duerinck, Alex Michotte, Anne Van Binst, Mark De Ridder, Bart Neyns.   

Abstract

Metastasis to the brain is a frequent event in patients with advanced melanoma. Despite treatment with neurosurgery, pancranial irradiation and high-precision conformal radiotherapy, the prognosis of patients suffering from melanoma brain metastasis has remained very poor. Ipilimumab is a new effective immunotherapy for the treatment of advanced melanoma and has demonstrated activity against brain metastases. We report three patients successfully treated with ipilimumab who subsequently developed focal necrosis of the brain following prior radiotherapy of their melanoma brain metastases. As new active systemic treatment options become available that improve the survival of patients with melanoma brain metastases, adequate diagnosis and management of the late sequela from radiation to the brain is likely to gain importance in the management of these patients.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22727601     DOI: 10.1016/j.ejca.2012.05.016

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  23 in total

Review 1.  Special topics in immunotherapy and radiation therapy: reirradiation and palliation.

Authors:  Tracey Evans; Christine Ciunci; Lauren Hertan; Daniel Gomez
Journal:  Transl Lung Cancer Res       Date:  2017-04

Review 2.  Radiotherapy and Immune Checkpoint Blockade for Melanoma: A Promising Combinatorial Strategy in Need of Further Investigation.

Authors:  Freddy E Escorcia; Michael A Postow; Christopher A Barker
Journal:  Cancer J       Date:  2017 Jan/Feb       Impact factor: 3.360

Review 3.  Immune Checkpoint Inhibitors for Brain Metastases.

Authors:  Aaron C Tan; Amy B Heimberger; Alexander M Menzies; Nick Pavlakis; Mustafa Khasraw
Journal:  Curr Oncol Rep       Date:  2017-06       Impact factor: 5.075

Review 4.  Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases.

Authors:  Kirtesh R Patel; David H Lawson; Ragini R Kudchadkar; Bradley C Carthon; Daniel E Oliver; Derick Okwan-Duodu; Rafi Ahmed; Mohammad K Khan
Journal:  Neuro Oncol       Date:  2015-05-25       Impact factor: 12.300

Review 5.  Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma.

Authors:  Christopher A Barker; Michael A Postow; Shaheer A Khan; Kathryn Beal; Preeti K Parhar; Yoshiya Yamada; Nancy Y Lee; Jedd D Wolchok
Journal:  Cancer Immunol Res       Date:  2013-07-25       Impact factor: 11.151

6.  Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma.

Authors:  E Liniker; A M Menzies; B Y Kong; A Cooper; S Ramanujam; S Lo; R F Kefford; G B Fogarty; A Guminski; T W Wang; M S Carlino; A Hong; G V Long
Journal:  Oncoimmunology       Date:  2016-08-19       Impact factor: 8.110

7.  Stereotactic radiosurgery and ipilimumab for patients with melanoma brain metastases: clinical outcomes and toxicity.

Authors:  Kevin Diao; Shelly X Bian; David M Routman; Cheng Yu; Jason C Ye; Naveed A Wagle; Michael K Wong; Gabriel Zada; Eric L Chang
Journal:  J Neurooncol       Date:  2018-04-25       Impact factor: 4.130

Review 8.  Updates in the management of brain metastases.

Authors:  Nils D Arvold; Eudocia Q Lee; Minesh P Mehta; Kim Margolin; Brian M Alexander; Nancy U Lin; Carey K Anders; Riccardo Soffietti; D Ross Camidge; Michael A Vogelbaum; Ian F Dunn; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2016-08       Impact factor: 12.300

Review 9.  Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes.

Authors:  Christopher A Barker; Michael A Postow
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-04-01       Impact factor: 7.038

10.  Combined radiotherapy with nivolumab for extracranial metastatic malignant melanoma.

Authors:  Tetsuya Komatsu; Kenta Konishi; Masahiro Aoshima; Yoshiki Tokura; Katsumasa Nakamura
Journal:  Jpn J Radiol       Date:  2018-09-11       Impact factor: 2.374

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.